Stay updated on Nivolumab Plus Ipilimumab in Metastatic Cancer Clinical Trial

Sign up to get notified when there's something new on the Nivolumab Plus Ipilimumab in Metastatic Cancer Clinical Trial page.
Latest website image capture
Clouds background image

Latest updates to the Nivolumab Plus Ipilimumab in Metastatic Cancer Clinical Trial page

  1. Check
    7 days ago
    No Change Detected
  2. Check
    14 days ago
    Change Detected
    Summary
    Added Revision: v3.4.2; removed the lapse-in-government-funding notice and Revision: v3.4.1.
    Difference
    0.4%
    Check dated 2026-02-11T10:01:33.000Z thumbnail image
  3. Check
    21 days ago
    Change Detected
    Summary
    Added a Publications reference for Larkin et al. (Combined Nivolumab and Ipilimumab in untreated melanoma) replacing the older Larkin et al. NEJM citation, and a site-wide notice about government funding and NIH status was also added.
    Difference
    0.4%
    Check dated 2026-02-04T06:49:29.000Z thumbnail image
  4. Check
    28 days ago
    Change Detected
    Summary
    Added glossary toggle label, Last Update Submitted that Met QC Criteria, No FEAR Act Data, and revised the page version to v3.4.0 (from v3.3.4). These changes are limited to UI text and metadata and do not alter the study content or results. To avoid being alerted by small changes, set an alert condition by clicking below.
    Difference
    0.2%
    Check dated 2026-01-28T04:48:23.000Z thumbnail image
  5. Check
    42 days ago
    Change Detected
    Summary
    Page revision updated from v3.3.3 to v3.3.4.
    Difference
    0.0%
    Check dated 2026-01-14T01:12:08.000Z thumbnail image
  6. Check
    49 days ago
    Change Detected
    Summary
    The Publications section now lists the Larkin et al. 2015 publication with an erratum, replacing the earlier entry; To avoid being alerted by small changes, set an alert condition by clicking below.
    Difference
    0.0%
    Check dated 2026-01-06T22:48:01.000Z thumbnail image
  7. Check
    64 days ago
    Change Detected
    Summary
    Locations section updated: added a general 'Locations' grouping and included CA, MA, NY, and TX; removed California/Massachusetts/New York/Texas locations. The footer revision changed to v3.3.3 and the HHS Vulnerability Disclosure link was removed.
    Difference
    0.5%
    Check dated 2025-12-23T09:11:15.000Z thumbnail image

Stay in the know with updates to Nivolumab Plus Ipilimumab in Metastatic Cancer Clinical Trial

Enter your email address, and we'll notify you when there's something new on the Nivolumab Plus Ipilimumab in Metastatic Cancer Clinical Trial page.